Delayed hypersensitivity to scopolamine delivered by a transdermal device.
Transdermal devices are now marketed for the delivery of systemic medications through the skin. This report confirms delayed hypersensitivity to scopolamine, the active ingredient in Transderm-Scop. Patch testing with structurally related alkaloids suggests the active antigenic site on the scopolamine molecule. The mechanism of drug delivery by the transdermal device is discussed, along with the features that make this an attractive method of drug administration. Dermatologists should be familiar with these devices, since broader future applications can be expected.
Trozak
D J
DJ
D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced*; D008875:Middle Aged; D010328:Patch Tests; D012601:Scopolamine / Q000008:administration & dosage / Q000009:adverse effects*
D012601:Scopolamine